title: Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus.
abstract: Both neutralizing and nonneutralizing immunoglobulin G2a monoclonal antibodies (MAs) directed against the E2 glycoprotein of Semliki Forest virus (SFV) protected mice prophylactically and therapeutically against virulent SFV infection. The neutralizing MAs, however, conferred protection to mice at lower doses than did nonneutralizing MAs. The antibody-dependent, complement-mediated cytolysis of SFV-infected L cells was effectuated by both kinds of antibodies, but again neutralizing MAs were more effective. Removal of the Fc part of the neutralizing MA UM 5.1 by pepsin digestion resulted in a 100-fold reduction of the neutralization titer (10(4) versus 10(6)) and a complete loss of its capacity to mediate antibody-dependent, complement-mediated cytolysis. Passive protection of infected mice occurred only after administration of relatively high doses of F(ab')2 of MA UM 5.1 (30.0 micrograms versus 0.1 microgram). F(ab')2 fragments prepared from the nonneutralizing MA UM 4.2 had lost their protective capacity completely. Surprisingly, the nonneutralizing MA UM 4.2 retarded virus growth in mouse fibroblasts (L cells), although inhibition was at much higher doses than with the neutralizing MA UM 5.1. Furthermore, both MAs promoted the uptake of virulent SFV in the Fc receptor-bearing WEHI-3 cells. The results suggest that nonneutralizing MAs protect mice not only by antibody-dependent, complement-mediated cytolysis but also by growth inhibition and enhanced uptake of SFV in the nonpermissive macrophages of BALB/c mice. This hypothesis is supported by the absence of viremia in recipients of nonneutralizing MA UM 4.2 at 24 h after infection.
authors.forename: W A
authors.initials: WA
authors.lastname: Boere
authors.forename: B J
authors.initials: BJ
authors.lastname: Benaissa-Trouw
authors.forename: T
authors.initials: T
authors.lastname: Harmsen
authors.forename: T
authors.initials: T
authors.lastname: Erich
authors.forename: C A
authors.initials: CA
authors.lastname: Kraaijeveld
authors.forename: H
authors.initials: H
authors.lastname: Snippe
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D004660:Encephalitis / Q000517:prevention & control; D007141:Immunoglobulin Fc Fragments / Q000502:physiology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D012672:Semliki forest virus / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity; D014036:Togaviridae Infections / Q000517:prevention & control*; D014766:Viremia / Q000517:prevention & control; D014774:Virulence
chemical_list: D000911:Antibodies, Monoclonal; D007141:Immunoglobulin Fc Fragments